Q4 2024 BioCardia Inc Earnings Call Transcript
Key Points
- BioCardia Inc (BCDA) reported a significant reduction in mortality rates in their CardiAMP HF clinical trial, which is a positive outcome in a field where no current therapy reduces mortality.
- The trial demonstrated meaningful reductions in major adverse cardiac events, which could potentially lower the cost of heart failure care.
- The CardiAMP HF trial showed a 47% relative risk reduction in heart death equivalents and a 16% relative risk reduction in major adverse cardiac events.
- The company observed a clinically meaningful 10.5% improvement in quality-of-life scores and a 13.9-meter improvement in the six-minute walk distance test.
- BioCardia Inc (BCDA) has a strong safety profile for their CardiAMP cell therapy, with trends indicating reduced cardiac arrhythmias, addressing a primary safety concern with cell therapy.
- The CardiAMP HF clinical trial did not meet its primary endpoint due to the six-minute walk distance test, which offset the benefits seen in other areas.
- The market reaction to the trial results was unexpectedly negative, despite the company achieving its anticipated outcomes.
- BioCardia Inc (BCDA) anticipates an increase in research and development expenses in 2025, which could impact financial performance.
- The company ended the year with cash and cash equivalents totaling only $2.4 million, indicating potential financial constraints.
- There is uncertainty regarding the timeline and outcome of regulatory discussions with the FDA and Japan's PMDA, which could affect the future availability of their therapies.
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the BioCardia year-end 2024 financial results and business update conference call. (Operator Instructions) A webcast replay of the call will be available approximately one hour after the end of the call. I would now like to send the call over to Miranda Peto of BioCardia Investor Relations. Please go ahead, Miranda.
Good afternoon and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer, and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements. Including statements that address BioCardia's expectations for future performance and operational results, references to management, intentions, beliefs, projections, outlook, analysis, and current expectations. Such factors include, among others, the inherent uncertainty associated with developing new products, technologies
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
